LEO is claiming global commercial rights to Spevigo for GPP but will also collaborate with Boehringer on potential follow-up ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

LEO Pharma retains the option to co-commercialise oral programmes for dermatology outside the US and will exclusively hold global rights to topical STAT6 formulations in dermatology.

Technology has also improved immunisation operations with the use of online appointment scheduling that automates ...

LEO Pharma presents late-breaking positive Phase 2a efficacy and safety results of LEO 138559 in moderate-to-severe atopic dermatitis ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.